Mega Lifesciences Public Company Limited (MEGA-R) - Net Assets

Latest as of June 2025: ฿9.95 Billion THB ≈ $310.02 Million USD

Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has net assets worth ฿9.95 Billion THB (≈ $310.02 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿14.31 Billion ≈ $446.11 Million USD) and total liabilities (฿4.37 Billion ≈ $136.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MEGA-R cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	฿9.95 Billion
% of Total Assets	69.49%
Annual Growth Rate	19.15%
5-Year Change	41.52%
10-Year Change	127.86%
Growth Volatility	31.58

Mega Lifesciences Public Company Limited - Net Assets Trend (2010–2024)

This chart illustrates how Mega Lifesciences Public Company Limited's net assets have evolved over time, based on quarterly financial data. Also explore Mega Lifesciences Public Company Limited asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Mega Lifesciences Public Company Limited (2010–2024)

The table below shows the annual net assets of Mega Lifesciences Public Company Limited from 2010 to 2024. For live valuation and market cap data, see market value of Mega Lifesciences Public Company Limited.

Year	Net Assets	Change
2024-12-31	฿9.88 Billion ≈ $307.85 Million	+6.18%
2023-12-31	฿9.30 Billion ≈ $289.94 Million	+5.99%
2022-12-31	฿8.78 Billion ≈ $273.56 Million	+9.37%
2021-12-31	฿8.03 Billion ≈ $250.14 Million	+14.99%
2020-12-31	฿6.98 Billion ≈ $217.53 Million	+13.02%
2019-12-31	฿6.18 Billion ≈ $192.47 Million	+7.87%
2018-12-31	฿5.72 Billion ≈ $178.42 Million	+9.15%
2017-12-31	฿5.24 Billion ≈ $163.46 Million	+12.06%
2016-12-31	฿4.68 Billion ≈ $145.87 Million	+7.96%
2015-12-31	฿4.33 Billion ≈ $135.11 Million	+8.96%
2014-12-31	฿3.98 Billion ≈ $124.00 Million	+7.74%
2013-12-31	฿3.69 Billion ≈ $115.09 Million	+127.06%
2012-12-31	฿1.63 Billion ≈ $50.69 Million	+23.36%
2011-12-31	฿1.32 Billion ≈ $41.09 Million	+55.11%
2010-12-31	฿849.90 Million ≈ $26.49 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Mega Lifesciences Public Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 774.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	฿7.76 Billion	78.52%
Other Components	฿2.12 Billion	21.48%
Total Equity	฿9.88 Billion	100.00%

Mega Lifesciences Public Company Limited Competitors by Market Cap

The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their market capitalization.

Company	Market Cap
Guangdong Great River Smarter Logistics Co Ltd Class A SHE:002930	$869.62 Million
BMC Medical Co. Ltd. A SHE:301367	$869.67 Million
Osisko Development Corp V:ODV	$870.11 Million
Lloyds Engineering Works Limited NSE:LLOYDSENGG	$870.15 Million
Jiangsu Lianyungang Port Co Ltd SHG:601008	$869.60 Million
Lotte Reit Co Ltd KO:330590	$869.49 Million
YALLA GROUP SP.ADS/1 CL.A F:80Q	$869.45 Million
Sichuan Guoguang Agrochemical Co Ltd SHE:002749	$869.41 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mega Lifesciences Public Company Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 9,302,162,000 to 9,876,759,000, a change of 574,597,000 (6.2%).
Net income of 2,012,481,000 contributed positively to equity growth.
Dividend payments of 1,394,568,000 reduced retained earnings.
Other comprehensive income decreased equity by 88,210,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	฿2.01 Billion	+20.38%
Dividends Paid	฿1.39 Billion	-14.12%
Other Comprehensive Income	฿-88.21 Million	-0.89%
Other Changes	฿44.89 Million	+0.45%
Total Change	฿-	6.18%

Book Value vs Market Value Analysis

This analysis compares Mega Lifesciences Public Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.82x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 18.03x to 2.82x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	฿1.77	฿32.00	x
2012-12-31	฿2.20	฿32.00	x
2013-12-31	฿4.94	฿32.00	x
2014-12-31	฿4.60	฿32.00	x
2015-12-31	฿5.01	฿32.00	x
2016-12-31	฿5.39	฿32.00	x
2017-12-31	฿6.04	฿32.00	x
2018-12-31	฿6.59	฿32.00	x
2019-12-31	฿7.09	฿32.00	x
2020-12-31	฿7.98	฿32.00	x
2021-12-31	฿9.18	฿32.00	x
2022-12-31	฿10.07	฿32.00	x
2023-12-31	฿10.67	฿32.00	x
2024-12-31	฿11.33	฿32.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mega Lifesciences Public Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 20.38%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.12%
• Asset Turnover: 1.08x
• Equity Multiplier: 1.44x
Recent ROE (20.38%) is below the historical average (21.85%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	35.19%	9.39%	1.48x	2.54x	฿326.33 Million
2012	34.66%	9.31%	1.44x	2.58x	฿395.32 Million
2013	16.90%	8.87%	1.08x	1.77x	฿254.76 Million
2014	13.77%	7.09%	1.15x	1.69x	฿150.05 Million
2015	16.05%	8.76%	1.04x	1.76x	฿262.28 Million
2016	16.99%	9.02%	1.11x	1.70x	฿326.93 Million
2017	21.22%	11.59%	1.10x	1.66x	฿588.36 Million
2018	21.07%	11.66%	1.07x	1.68x	฿633.58 Million
2019	18.44%	10.23%	1.06x	1.71x	฿521.02 Million
2020	20.02%	11.06%	1.09x	1.67x	฿696.89 Million
2021	24.33%	13.77%	1.07x	1.66x	฿1.15 Billion
2022	25.54%	14.29%	1.07x	1.67x	฿1.36 Billion
2023	21.42%	12.71%	1.08x	1.56x	฿1.06 Billion
2024	20.38%	13.12%	1.08x	1.44x	฿1.02 Billion

Industry Comparison

This section compares Mega Lifesciences Public Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,478,056,000
Average return on equity (ROE) among peers: 17.28%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Mega Lifesciences Public Company Limited (MEGA-R)	฿9.95 Billion	35.19%	0.44x	$869.61 Million
Eternal Energy Public Company Limited (EE)	$179.38 Million	9.03%	2.06x	$36.39 Million
Mega Lifesciences Public Company Limited (MEGA)	$8.78 Billion	25.54%	0.67x	$971.52 Million

About Mega Lifesciences Public Company Limited

BK:MEGA-R Thailand Drug Manufacturers - Specialty & Generic

Market Cap

$869.61 Million

฿27.90 Billion THB

Market Cap Rank

#9754 Global

#82 in Thailand

Share Price

฿32.00

Change (1 day)

+0.00%

52-Week Range

฿24.50 - ฿32.00

All Time High

฿52.19